Anticoagulation Transitions: Perioperative Care Alan Brush, MD, FACP Clinical Co-Director, Anticoagulation Management Service Harvard Vanguard Medical.

Slides:



Advertisements
Similar presentations
New Atrial Fibrillation/Flutter Pathway and GRASP Tool
Advertisements

DURNER L.,BOURDOUMIS A., MASOOD J., BUCHHOLZ N. ROYAL LONDON HOSPITAL, BARTSHEALTH NHS TRUST ROYAL DEVON AND EXETER NHS TRUST HOMERTON UNIVERSITIY HOSPITAL.
Bridge Therapy: Peri-operative Anticoagulation Management Amjad AlMahameed, MD, MPH Division of Cardiology Beth Israel Deaconess Medical Center Boston.
Leadership. Knowledge. Community. Canadian Cardiovascular Society Antiplatelet Guidelines COMBINATION WARFARIN + ASA THERAPY WHEN: TO USE, TO CONSIDER,
CLINICAL CASES.
Perioperative Medicine Beyond Cardiac Clearance Pamela Pride MD July 31, 2012 MUSC.
Division of Population Health Sciences Royal College of Surgeons in Ireland Coláiste Ríoga na Máinleá in Éirinn A Systematic Review of the CHADS 2 Score.
Stroke prevention in atrial fibrillation
AF and NOACs An UPDATE JULY 2014
CHEST-2012: High Points and Pearls Alan Brush, MD, FACP Chief, Anticoagulation Management Service Harvard Vanguard Medical Associates.
Venous thromboembolism: how long to treat?
Evidence That D-dimer Levels Predict Subsequent Thromboembolic and Cardiovascular Events in Patients with Atrial Fibrillation during Oral Anticoagulant.
Surgery with a Prosthetic Valve- What about the Warfarin? COPYRIGHT © 2014, ALL RIGHTS RESERVED From the Publishers of.
Anticoagulation Bridging Decision Support
Management thrombophilia. introduction Twenty percent of maternal deaths in the United States during that period were attributed to PE. Inherited thrombophilias.
Supervisor: Vs 余垣斌 Presenter: CR 周益聖. INTRODUCTION.
Indications for Perioperative Bridging Ann McBride, M.D. UW Anticoagulation Service.
Peri-operative management of anticoagulation Marc Carrier MD, MSc FRCPC Assistant Professor, University of Ottawa Associate Scientist, Ottawa Health Research.
Perioperative Medicine Beyond Cardiac Clearance Pamela Pride MD July 31, 2012 MUSC.
Bridging Oral Anticoagulation with Low Molecular Weight Heparin: Experience in 367 Patients with Renal Insufficiency Heyder Omran, Giso von der Recke,
PreOp Anticoagulation Decision Support Click here to begin Click here for references.
Global Variations in the 1-year Rates of Death and Stroke in Patients Presenting to the Emergency Department with Atrial Fibrillation Results from the.
Chapter Seven Venous Disease Coalition Long-Term Management of VTE VTE Toolkit.
How Do You Manage Anticoagulants and Antiplatlet Agents? Steve Schrock, MD, FAAFP November 5, 2015.
Peri-Operative anticoagulation /antiplatelet therapy A Shift in Paradigm BMHGT04/29/09.
Perioperative Medicine Beyond Cardiac Clearance Pamela Pride MD July 31, 2012 MUSC.
General principles for preventing high INR Simple dental or dermatological procedures may not require interruption to warfarin therapy. Simple dental.
Perioperative Management of Antithrombotic Therapy Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians.
The Case for Rate Control: In the Management of Atrial Fibrillation Charles W. Clogston, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April.
Antithrombotic Therapy for VTE: CHEST Guidelines 2016
Antithrombotic Therapy in Atrial Fibrillation Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention of Thrombosis,
Antithrombotic and Thrombolytic Therapy for Valvular Disease Copyright: American College of Chest Physicians 2012 © Antithrombotic Therapy and Prevention.
Warfarin PSD/HOF001/GB/DC/Rev013 Issued : Review interval:12 months This document may be reviewed and reissued electronically without notice.
Antithrombotic and Thrombolytic Therapy for Ischemic Stroke Antithrombotic Therapy and Prevention of Thrombosis: ACCP Evidence-Based Clinical Practice.
Nathan P. Clark, Pharm D, FCCP, BCPS Clinical Pharmacy Supervisor Clinical Pharmacy Anticoagulation and Anemia Service Kaiser Permanente Colorado Aurora,
G UIDELINES FOR THE P ERI -P ROCEDURAL M ANAGEMENT OF A DULTS T AKING T ARGET S PECIFIC A NTICOAGULANTS (TSOAC S ): DABIGATRAN, RIVAROXABAN, APIXABAN,
ResultsIntroduction Atrial Fibrillation (AF) affects 1.2% 1 of the population and 10% of those over the age of 75 2 It is the commonest arrhythmia in primary.
Case 1 Shahinda wahba 5033 Dina bawahab 5090 Wid nahas 5069 Doaa bayumi 5580 Ayat al-hindy Latifa abdulrahman.
Warfarin Therapy Aaqid Akram MBChB (2013) Clinical Education Fellow.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. Benefit of Anticoagulation Unlikely in Patients With Atrial.
Treatment of deep venous thrombosis and pulmonary embolism Anders Waage.
Antithrombotic and Thrombolytic Therapy for Valvular Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest.
Outpatient DVT assessment & treatment Daniel Gilada.
Γεώργιος Ντάιος Παθολογική Κλινική, Πανεπιστήμιο Θεσσαλίας Διαχείριση αντιπηκτικής αγωγής εν όψει προγραμματισμένων επεμβατικών πράξεων.
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation NEJM Aug 27, 2015.
Dep. Of Hemato-Oncology R1. Choi In-Ah D-dimer Testing to Determine the Duration of Anticoagulation Therapy Gualtiero Palareti,M.D., Benilde Cosmi, M.D.,
Dr. Hadab A. Mohamed. BACKGROUND Temporary interruption Thrombotic risk Continuation Bleeding risk A great challenge, especially in the emergency setting.
Introduction - Perioperative management of patients on warfarin or antiplatelet therapy involves assessing and balancing individual risks for thromboembolism.
© free-ppt-templates.com 2017 AHA/ACC Focused Update of Valvular Heart Disease Guideline of 2014 DR. OMAR SHAHID TR CARDIOLOGY SZH.
Low Procedural Bleed Risk
Preoperative Assessment
Perioperative Management of Antithrombotic Therapy
You can never be too Thin…. An Update on NOACs
Is There a Need to Address AF in patients Undergoing Valve Surgery?
A Comparison of RE-LY and ROCKET AF Trial Designs and Outcomes
Guide on how to manage atrial fibrillation in the office
Dr Ferdous Mehrabian. Dr Ferdous Mehrabian Inherited thrombophilias in pregnancy Inherited thrombophilias is a genetic tendency to venous thrombosis.
Fibrillazione atriale
Selecting NOACs for High-Risk Patients
Gregory Y.H. Lip, MD, Jonathan L. Halperin, MD, Hung-Fat Tse, MD, PhD 
Cancer-Associated Thrombosis
Bridging Anticoagulation
Isla M. Ogilvie, PhD, Nick Newton, PhD, Sharon A
Optimizing Atrial Fibrillation Management
Antithrombotic therapy and oral surgery
5 Good Minutes on Atrial Fibrillation-related Stroke
Thrombophilia in pregnancy: Whom to screen, when to treat
Figure 8. Stroke prevention strategy in patients with AF
Figure 1. Decision-making process of stroke prevention in patients with AF from Asia. The decision-making process includes stroke risk evaluation, OAC.
NICE 2014 Check pulse in patients presenting with:
Presentation transcript:

Anticoagulation Transitions: Perioperative Care Alan Brush, MD, FACP Clinical Co-Director, Anticoagulation Management Service Harvard Vanguard Medical Associates

Four Questions for each Consultation… 1.Is anticoagulation appropriate for this patient? 2.Does procedure require holding warfarin? 3.Does patient require a “bridge”? 4.When can anticoagulation restart? 1.Is anticoagulation appropriate for this patient? 2.Does procedure require holding warfarin? 3.Does patient require a “bridge”? 4.When can anticoagulation restart?

Question 1… Is anticoagulation appropriate for this patient? Transitions offer a golden opportunity to re- examine the clinical indications for anticoagulation in our patients. Due to changes in a patient’s clinical status or even changes in guidelines, anticoagulation may no longer be appropriate. Is anticoagulation appropriate for this patient? Transitions offer a golden opportunity to re- examine the clinical indications for anticoagulation in our patients. Due to changes in a patient’s clinical status or even changes in guidelines, anticoagulation may no longer be appropriate.

Question 2… Does procedure require holding warfarin? The bleeding risk of the procedure determines whether or not a hold in anticoagulation is required, and if so, for how long. The range of bleeding risk extends from low risk not requiring hold (cataract and most dental surgery) to extremely high risk requiring a prolonged hold (spinal surgery). Does procedure require holding warfarin? The bleeding risk of the procedure determines whether or not a hold in anticoagulation is required, and if so, for how long. The range of bleeding risk extends from low risk not requiring hold (cataract and most dental surgery) to extremely high risk requiring a prolonged hold (spinal surgery).

Dental Surgery SAFETY OF OUTPATIENT DENTAL TREATMENT FOR PATIENTS ON COUMADIN (WARFARIN) THERAPY SAFETY OF OUTPATIENT DENTAL TREATMENT FOR PATIENTS ON COUMADIN (WARFARIN) THERAPY DENTAL TREATMENT SUBOPTIMAL INR RANGE NORMAL TARGET INR RANGE MAY BE NORMAL TARGET WITH MECHANICAL HEART VALVE OUT OF RANGE < >3.5 Exam, X-Ray, Study Models SAFE INSUFFICIENT RESEARCH Simple restoration, supragingival prophylaxis SAFE NOT ADVISED NOT ADVISED Complex restoration, scaling, root planing, endodontics SAFE INSUFFICIENT RESEARCH INSUFFICIENT RESEARCH NOT ADVISED NOT ADVISED Simple extraction, curettage, gingivoplasty SAFE LOCAL MEASURES LOCAL MEASURES LOCAL MEASURES LOCAL MEASURES NOT ADVISED NOT ADVISED Multiple extractions, removal of single bony impaction SAFE LOCAL MEASURES LOCAL MEASURES LOCAL MEASURES LOCAL MEASURES LOCAL MEASURES LOCAL MEASURES NOT ADVISED NOT ADVISED

Question 3… Does patient require a “bridge”? Need for “bridging” depends on the duration of the anticipated hold and the thrombotic risk of the patient. Any procedure with a high bleeding risk will be likely to require a more prolonged hold; but the main decision depends on thrombotic risk stratification. Does patient require a “bridge”? Need for “bridging” depends on the duration of the anticipated hold and the thrombotic risk of the patient. Any procedure with a high bleeding risk will be likely to require a more prolonged hold; but the main decision depends on thrombotic risk stratification.

Risk Stratification for Perioperative Care Low Bileaflet aortic valve prosthesis without atrial fibrillation and no other risk factors for stroke -CHADS 2 score of 0 to 2 (and no prior stroke or transient ischemic attack) Single VTE occurred > 12 mo ago and no other risk factors Medium -Bileaflet aortic valve prosthesis and one of the following: atrial fibrillation, prior stroke or transient ischemic attack, hypertension, diabetes, congestive heart failure, age >75yr -CHADS 2 score of 3 or 4 -VTE within the past 3 to 12 mo -Non-severe thrombophilic conditions (e.g., heterozygous factor V Leiden mutation, heterozygous factor II mutation) -Recurrent VTE -Active cancer (treated within 6 months or palliative) -VTE within the past 3 to 12 mo -Non-severe thrombophilic conditions (e.g., heterozygous factor V Leiden mutation, heterozygous factor II mutation) -Recurrent VTE -Active cancer (treated within 6 months or palliative) High -Any mitral valve prosthesis -Older (caged-ball or tilting disc) aortic valve prosthesis -Recent (within 6 mo) stroke or transient ischemic attack -Any mitral valve prosthesis -Older (caged-ball or tilting disc) aortic valve prosthesis -Recent (within 6 mo) stroke or transient ischemic attack - CHADS2 score of 5 or 6 -Recent (within 3 mo) stroke or transient ischemic attack, -Rheumatic valvular heart disease - CHADS2 score of 5 or 6 -Recent (within 3 mo) stroke or transient ischemic attack, -Rheumatic valvular heart disease -Recent (within 3 mo) VTE -Severe thrombophilia (eg, deficiency of protein C, protein S or antithrombin, antiphospholipid antibodies, or multiple abnormalities) -Recent (within 3 mo) VTE -Severe thrombophilia (eg, deficiency of protein C, protein S or antithrombin, antiphospholipid antibodies, or multiple abnormalities) Mechanical Heart Valve Atrial Fibrillation VTE Indication for VKA Therapy

CHAD-2 Risk Factors and Score CHAD-2 Stroke Risk Factors Score Congestive heart failure +1 Hypertension +1 Age 75 years or older +1 Diabetes mellitus +1 History of stroke or TIA +2 Score Risk of a Stroke 0-2 low 3-5 medium 6 6 high

CHAD-2 Score, Estimated Strokes, Prevented Strokes Score Estimated % with stroke at 1 year Estimated prevented strokes/1000 patients/year Estimated % with stroke in 1 week Estimated % with stroke in 2 weeks Estimated prevented strokes/1000 patients/2 weeks < < < % with Stroke at 1.2 years

Question 4… When can anticoagulation be resumed? Warfarin can generally be resumed 12 to 24 hours after surgery, once hemostasis has been secured, realizing that it will take two days to reach a partial anticoagulation effect. If surgery is major, LMWH may require a more prolonged hold, so decision for resumption requires the surgeon’s assessment of post-operative bleeding risk. When can anticoagulation be resumed? Warfarin can generally be resumed 12 to 24 hours after surgery, once hemostasis has been secured, realizing that it will take two days to reach a partial anticoagulation effect. If surgery is major, LMWH may require a more prolonged hold, so decision for resumption requires the surgeon’s assessment of post-operative bleeding risk.

Cases 5, 6, and 7 Questions?…

The End